Vistagen Therapeutics, Inc. (VTGN)
NASDAQ: VTGN · Real-Time Price · USD
0.7020
+0.0854 (13.85%)
At close: Jun 26, 2026, 4:00 PM EDT
0.7400
+0.0380 (5.41%)
After-hours: Jun 26, 2026, 7:59 PM EDT

Vistagen Therapeutics Balance Sheet

Millions USD. Fiscal year is Apr - Mar.
Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Cash & Equivalents
30.7967.13119.1716.6468.14
Short-Term Investments
14.6113.35---
Cash & Short-Term Investments
45.480.48119.1716.6468.14
Cash Growth
-43.59%-32.46%616.23%-75.58%-33.92%
Other Current Assets
1.541.591.510.872.86
Total Current Assets
46.9482.08120.6717.5171
Net Property, Plant & Equipment
1.231.812.262.773.08
Other Long-Term Assets
0.390.450.730.820.57
Total Assets
48.5684.34123.6521.0974.64
Accounts Payable
1.540.651.552.472.76
Accrued Expenses
8.768.812.240.81.33
Short-Term Debt
0.1--0.11-
Current Portion of Leases
0.70.560.550.490.43
Unearned Revenue
1.712.590.790.711.24
Total Current Liabilities
12.812.615.124.575.77
Long-Term Leases
0.250.951.572.122.61
Other Long-Term Liabilities
-0.392.672.321.56
Total Long-Term Liabilities
0.251.344.244.444.16
Total Liabilities
13.0413.959.379.019.93
Common Stock
--0.030.010.01
Treasury Stock
-3.97-3.97-3.97-3.97-3.97
Additional Paid-in Capital
516.77481.96474.44342.89336.28
Accumulated Other Comprehensive Income
-00.01---
Retained Earnings
-477.32-407.63-356.21-326.85-267.6
Shareholders' Equity
35.5270.39114.2912.0864.72
Total Liabilities & Equity
48.5684.34123.6521.0974.64
Total Debt
1.041.512.122.713.04
Net Cash (Debt)
44.3678.97117.0513.9365.1
Net Cash Growth
-43.83%-32.53%740.43%-78.61%-34.50%
Net Cash Per Share
1.172.566.052.009.86
Book Value
35.5270.39114.2912.0864.72
Book Value Per Share
0.932.285.901.749.81
Tangible Book Value
35.5270.39114.2912.0864.72
Tangible Book Value Per Share
0.932.285.901.749.81
SEC Filings: 10-K · 10-Q